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The genetic makeup of an individual contributes to susceptibility and response to viral infection. While 
environmental, clinical and social factors play a role in exposure to SARS-CoV-2 and COVID-19 disease 
severity, host genetics may also be important. Identifying host-specific genetic factors indicate biological 
mechanisms of therapeutic relevance and clarify causal relationships of modifiable environmental risk 
factors for SARS-CoV-2 infection and outcomes. We formed a global network of researchers to investigate 
the role of human genetics in SARS-COV-2 infection and COVID-19 severity. We describe the results of 
three genome-wide association meta-analyses comprising 49,562 COVID-19 patients from 46 studies 
across 19 countries worldwide. We reported 15 genome-wide significant loci that are associated with 
SARS-CoV-2 infection or severe manifestations of COVID-19. Several of these loci correspond to 
previously documented associations to lung or autoimmune and inflammatory diseases. They also represent 
potentially actionable mechanisms in response to infection. We further identified smoking and body mass 
index as causal risk factors for severe COVID-19. The identification of novel host genetic factors associated 
with COVID-19, with unprecedented speed, was enabled by prioritization of shared resources and analytical 
frameworks. This working model of international collaboration a blue-print for future genetic discoveries 






The coronavirus disease 2019 (COVID-19) pandemic, caused by infections with severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has resulted in enormous health and economic burden worldwide. 
One of the most remarkable features of SARS-CoV-2 infection is that a large proportion of individuals 1 
are asymptomatic while others experience progressive, even life-threatening, viral pneumonia and acute 
respiratory distress syndrome. While established host factors contribute to disease severity (e.g., increasing 
age, male gender, and higher body mass index 2), these risk factors alone do not explain all variability in 
disease severity observed among individuals. 
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The contribution of host genetics to susceptibility and severity of infectious disease is well-documented, 
and encompasses rare inborn errors of immunity 3,4 as well as common genetic variation 5–10. Characterizing 
which genetic factors contribute to COVID-19 susceptibility and severity may uncover novel biological 
insights into disease pathogenesis and identify mechanistic targets for therapeutic development or drug 
repurposing, as treating the disease remains a highly important goal despite the recent development of 
vaccines. For example, rare loss-of-function variants in genes involved in type I interferon (IFN) response 
may be involved in severe forms of COVID-19 11–14. At the same time, several genome-wide association 
studies (GWAS) that investigate the contribution of common genetic variation 15–18 to COVID-19 have 
provided support for the involvement of several genomic loci associated with COVID-19 severity and 
susceptibility, with the strongest and most robust finding at locus 3p21.31. However, much remains 
unknown about the genetic basis of susceptibility to SARS-CoV-2 and severity of COVID-19.  
 
The COVID-19 Host Genetics Initiative (COVID-19 HGI) (https://www.covid19hg.org/) 19 is an 
international, open-science collaboration to share scientific methods and resources with research groups 
across the world with the goal to robustly map the host genetic determinants of SARS-CoV-2 infection and 
severity of the resulting COVID-19 disease. We have carefully aligned phenotype definitions and 
incorporated variable ascertainment strategies to achieve greater statistical confidence in our results. We 
openly and continuously share updated results to the research community. Here, we report the latest results 




Figure 1. Geographical overview of the contributing studies to the COVID-19 HGI and composition by 
major ancestry groups. Middle Eastern (MID), South Asian (SAS), East Asian (EAS), African (AFR), 
Admixed American (AMR), European (EUR). 
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Worldwide meta-analyses of COVID-19 
 
Overall, the COVID-19 Host Genetics Initiative combined genetic data for up to 49,562 cases and two 
million controls across 46 distinct studies (Fig. 1). The data included studies from populations of different 
genetic ancestries, including European, Admixed American, African, Middle Eastern, South Asian and East 
Asian individuals (Supplementary Table 1). We performed case-control meta-analyses in three main 
categories of COVID-19 disease according to predefined and partially overlapping phenotypic criteria. 
These were (1) critically ill COVID-19 cases defined as those who required respiratory support in hospital 
or who were deceased due to the disease, (2) cases with moderate or severe COVID-19 defined as those 
hospitalized due to symptoms associated with the infection, and (3) all cases with reported SARS-CoV-2 
infection with or without symptoms of any severity (Methods). Controls for all three analyses were selected 
as genetically ancestry-matched samples without known SARS-CoV-2 infection, if that information was 
available (Methods). Each individual study that contributed data to a particular analysis met a minimum 
threshold of 50 cases, as defined by the aforementioned phenotypic criteria, for statistical robustness. Where 
more detailed demographic data was available, the average age of COVID-19 cases was 55.3 years 
(Supplementary Table 1).  
 
Across our three analyses, we reported a total of 15 independent genome-wide significant loci associated 
with COVID-19 (Table 1, Supplementary Table 2), most of which were shared between two or more 
COVID-19 phenotypes. Specifically, we reported six genome-wide significant (P < 5 × 10-8) associations 
for critical illness due to COVID-19, using data for 6,179 cases and 1,483,780 controls from 16 studies. 
Eleven genome-wide significant loci were detected for moderate to severe hospitalized COVID-19, from 
an analysis of 13,641 COVID-19 cases and 2,070,709 controls, across 29 studies (Fig. 2 top panel). Finally, 
eight loci reached genome-wide significance in the analysis using data for all available 49,562 reported 




Comparison of effect for genome-wide significant results across studies and phenotype definitions 
 
We found no genome-wide significant sex-specific effects at the 15 loci. However, we did identify 
significant heterogeneous effects (P <0.003) across studies for 3 out of the 15 loci, likely reflecting 
heterogeneous ascertainment of cases across studies contributing data to these analyses (Table 1). Two 
additional loci reached genome-wide significance but showed extreme heterogeneity across contributing 
studies (Fig 2); these loci were removed from downstream analyses and are not reported among the genome-
wide significant results in Table 1. There was minor sample overlap (n = 8,380 EUR; n = 745 EAS) between 
controls from the genOMICC and the UK Biobank studies, but leave-one-out sensitivity analyses did not 
reveal any bias in the corresponding effect sizes or P-values (Extended Data Fig. 1).   
 
We next wanted to better understand whether the 15 loci were acting through mechanisms increasing 
susceptibility to infection or by affecting the progression of symptoms towards more severe disease. For all 
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15 loci, we compared the lead variant (strongest association P-value) odds ratios (ORs) for the risk-
increasing allele across our different COVID-19 phenotype definitions.  
 
We first noted that four loci had consistent ORs between the two larger and better powered analyses; all 
cases with reported infection and all cases hospitalized due to COVID-19 (Methods) (Table 1, 
Supplementary Table 2). Such consistency implied that these four loci were likely associated with overall 
susceptibility to SARS-CoV-2 infection, but not with the progression to more severe COVID-19 
phenotypes. Notably, these susceptibility loci included the previously reported ABO locus 15,16,18,20. The lead 
variant rs912805253 at this locus reached genome-wide significance in both our reported infection (OR 
[95%CI] = 0.90 [0.89, 0.92]; P =1.4 × 10-39) and hospitalized COVID-19 (OR [95%CI] = 0.90 [0.87, 0.93]; 
P =5.4 × 10-10) analyses, but the odds of becoming hospitalized were no different from the odds of becoming 
infected when carrying this allele. 
 
In contrast, 11 out of the 15 loci were associated with increased risk of severe symptoms with significantly 
larger ORs for hospitalized COVID-19 compared to the mildest phenotype of reported infection (P <0.003 
(0.05/15) test for effect size difference) (Table 1, Supplementary Table 2). We further compared the ORs 
for these 11 loci for critical illness due to COVID-19 vs. hospitalized due to COVID-19, and found that 
these loci exhibited a general increase in effect risk for critical illness (Methods) (Extended Data Fig. 2A, 
Supplementary Table 3). These results indicated that these eleven loci were more likely associated with 
progression of the disease and worse outcome from SARS-CoV-2 infection compared to being associated 
with susceptibility to SARS-CoV-2 infection. We noted that two loci, tagged by lead variants rs1886814 
and rs72711165, were identified primarily from East Asian genetic ancestry samples (n = 1,414 cases 
hospitalized due to COVID-19) with minor allele frequencies in European populations being < 3%. This 
highlights the value of including data from diverse populations for genetic discovery. Another locus at 
3p21.31, which is the strongest, most replicated signal for COVID-19 severity 15–18,20, showed substantial 
differences in allele frequency across ancestry groups, probably explained by its recent introgression 21. We 
explored the effect of this locus in the Bangladeshi population, which carries the highest frequency for this 
haplotype in 1000 Genomes. Using data from the East London Genes & Health study 22 for a proxy variant 
rs34288077 in the locus (r2=0.99 to our lead variant rs10490770), we found that in British-Bangladeshi 
individuals, the variant frequency was 34.6% of the hospitalized COVID-19 positive patients (n = 76) 
compared to 23.8% in non-hospitalized population (n = 22,215) (OR [95%CI] = 2.11 [1.39, 3.21]; P =4.7 
× 10-4). 
 
Our phenotype definitions include population controls without known SARS-CoV-2 infection. This is not 
an optimal control group because some individuals, if exposed to SARS-CoV-2 could develop a severe 
form of COVID-19 disease and should be classified as cases. To better understand the effect of such 
potential misclassification, we conducted a new meta-analysis, including only the studies that compared 
hospitalized COVID-19 cases with controls with laboratory-confirmed SARS-CoV-2 infection but who had 
mild symptoms or were asymptomatic (n = 5,773 cases and n = 15,497 controls). We then compared the 
effect sizes obtained from this analysis with those from the main phenotype definition (hospitalized cases 
vs. controls without known SARS-CoV-2 infection, if that information was available) using only studies 
that reported results for both analyses (Methods). We found that across the 11 loci that had reached 
genome-wide significance in our main hospitalized COVID-19 analysis, the ORs were not significantly 
different in the analysis with better refined controls (Extended Data Fig. 2B, Supplementary Table 3). 
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These results indicate that using population controls can be a valid and powerful strategy for host genetic 




Table 1: Genome-wide significant results for each worldwide meta-analysis.  
Meta-analysis results that reached genome-wide significance are coloured in black; associations not 
reaching significance threshold of P < 5 × 10-8 are coloured in grey. Effect allele frequency is the sample 
size weighted frequency across studies included in each meta-analysis. P-value is reported for meta-
analysis variant association with trait (P-value association) and heterogeneity (P-value het) between 
studies included in each meta-analysis. Suggested phenotypic impact of the locus was inferred using a test 
comparing variant effects across analyses (see Methods). Closest gene: A gene with a minimum distance 
from each lead variant to gene body. Genes in linkage disequilibrium (LD) region: Genes that overlap with 
a genomic range that contains any variants in LD (r2 > 0.6) with each lead variant. Genes with coding 
variants: Genes with a loss-of-function or missense variant in LD with a lead variant (r2 > 0.6). eGenes: 
Genes with a fine-mapped cis-eQTL variant (PIP > 0.1) in GTEx Lung that is in LD with a lead variant (r2 
> 0.6). V2G: Highest gene prioritized by OpenTargetGenetics’ V2G score. 
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Figure 2. Genome-wide association results for COVID-19. Top panel shows results of genome-wide 
association study of hospitalized COVID-19 and controls, and bottom panel the results of reported SARS-
CoV-2 infection and controls. Eleven loci highlighted in yellow (top panel) represent regions associated 
with severity of COVID-19 manifestation i.e. increasing odds for more severe COVID-19 phenotypes, 
where loci highlighted in green (bottom panel) are regions associated with reported SARS-CoV-2 infection, 
i.e. the effect is the same across mild and severe COVID-19 phenotypes. A window of  +/- 500kb region 
from the lead variant (Table 1) was used to highlight these loci. Variants highlighted in red represent 
genome-wide significant variants that had high heterogeneity across studies that contributed data, and 
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Gene prioritization and association with other diseases or traits 
  
To better understand the potential biological mechanism of each locus, we applied several approaches to 
prioritize candidate causal genes and explore additional associations with other complex diseases and traits. 
For gene prioritization, we first identified genes within each COVID-19 associated region by distance or 
linkage disequilibrium (LD) to a lead variant, and then prioritized those with protein-alternating variants, 
lung eQTLs, or having the highest prioritization score in the OpenTargets V2G (Variant-to-Gene) algorithm 
23 (see Methods, Supplementary Tables 2 and 4). For reporting PheWAS associations (Supplementary 
Table 5), we only considered phenotypes for which the lead variants were in high LD (r2 > 0.8) with the 
15 genome-wide significant lead variants from our main COVID-19 meta-analysis. This conservative 
approach allowed spurious signals primarily driven by proximity rather than actual colocalization to be 
removed (see Methods). 
  
Of the 15 genome-wide significant loci, we found nine loci to have a distinct candidate gene(s), including 
biologically plausible genes (Table 1). Protein-altering variants in LD with lead variants implicated genes 
at six loci, including TYK2 (19p13.2) and PPP1R15A (19q13.33). The COVID-19 lead variant 
rs74956615:T>A in TYK2 , which confers risk for critical illness (O[95%] = 1.43 [1.29, 1.59]; P = 9.71 × 
10–12) and hospitalization (OR [95%CI] = 1.27 [1.18, 1.36]; P = 5.05 × 10–10) due to COVID-19, is 
correlated with the missense variant rs34536443:G>C (p.Pro1104Ala; r2 = 0.82) . This is consistent with 
the primary immunodeficiency described with complete TYK2 loss of function 24. In contrast, this missense 
variant was previously reported to be protective against autoimmune diseases, including rheumatoid 
arthritis (OR = 0.74; P = 3.0 × 10–8; UKB SAIGE), and hypothyroidism (OR = 0.84; P = 1.8 × 10–10; UK 
Biobank) (Fig. 3). An additional independent missense variant rs2304256:C>A (p.Val362Phe; r2 = 0.08 
with rs34536443) in TYK2 was also associated with critical illness (OR [95%] = 1.17 [1.11, 1.23]; P = 2.4 
× 10–10). At the 19q13.33 locus, the lead variant rs4801778, that was significantly associated with reported 
infection (OR [95%CI] = 0.95 [0.93, 0.96]; P = 2.1 × 10–8), is in LD (r2 = 0.93) with a missense variant 
rs11541192:G>A (p.Gly312Ser) in PPP1R15A. In an additional lookup, this missense variant was 
significantly associated with  reticulocyte count and strongly correlated with a reticulocyte lead variant 
rs56104184:C>T (beta= 0.033; P = 4.1 × 10–13 )25.  
 
Lung-specific cis-eQTL from GTEx v8  26 (n = 515) and the Lung eQTL Consortium 27 (n = 1,103) provided 
further support for a subset of loci, including FOXP4 (6p21.1) and ABO (9q34.2), OAS1/OAS3/OAS2 
(12q24.13), and IFNAR2/IL10RB (21q22.11), where the COVID-19 associated variants modifies gene 
expression in lung. Furthermore, our PheWAS analysis implicated three additional loci related to lung 
function, with modest lung eQTL evidence, i.e. the lead variant was not fine-mapped but significantly 
associated. An intronic variant rs2109069:G>A in DPP9 (19p13.3), positively associated with critical 
illness, was previously reported to be risk-increasing for interstitial lung disease (tag lead variant 
rs12610495:A>G [p.Leu8Pro], OR = 1.29, P =2.0 × 10-12) 28. The COVID-19 lead variant rs1886814:A>C 
in FOXP4 locus is modestly LD-linked (r2 = 0.64) with a lead variant of lung adenocarcinoma (tag 
variant=rs7741164; OR=1.2, P=6.0 × 10-13) 29.  We also found that intronic variants rs67579710:A>T in 
THBS3 (1q22) and rs1819040:T>A in KANSL1 (17q21.31), associated protectively against hospitalization 
due to COVID-19, were previously reported for reduced lung function (e.g. tag lead variant 
rs141942982:G>T, beta = –3.6 × 10–2, P = 1.00 × 10–20) 30. Notably, the 17q21.31 locus is a well-known 
locus for structural variants containing a megabase inversion polymorphism (H1 and inverted H2 forms) 
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and complex copy-number variations, where the inverted H2 forms were shown to be positively selected in 
Europeans 31,32. 
  
Lastly, there are remaining six loci with varying evidence for candidate causal genes. For example, the 
3p21.31 locus has a complex structure with varying genes prioritized by different methods, where we 
prioritized CXCR6 with the Variant2Gene (V2G) algorithm 23, while LZTFL1 is the closest gene. The 
CXCR6 plays a role in chemokine signaling 33, and LZTFL1 has been implicated in lung cancer 34. 
Nonetheless, these results provide supporting in-silico evidence for candidate causal gene prioritization, 
while we strongly need further functional characterization. Detailed locus descriptions and LocusZoom 
plots are provided in Extended Data Fig. 3. 
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Figure 3. Gene prioritization and PheWas. A) Gene prioritization using different evidence measures of 
gene annotation. The ideogram shows the position of the COVID-19 index SNPs and associated genes with 
type of gene annotation highlighted as stars. The squares above the SNP rsid represent COVID-19 sub-
phenotypes for which the SNP is genome-wide significant. Closest gene: A gene with a minimum distance 
from each lead variant to gene body. Genes in linkage disequilibrium (LD) region: Genes that overlap with 
a genomic range that contains any variants in LD (r2 > 0.6) with each lead variant. Genes with coding 
variants: Genes with a loss-of-function or missense variant in LD with a lead variant (r2 > 0.6). eGenes: 
Genes with a fine-mapped cis-eQTL variant (PIP > 0.1) in GTEx Lung that is in LD with a lead variant (r2 
> 0.6) (see Supplementary Table 4 for a complete list). V2G: Highest gene prioritized by 
OpenTargetGenetics’ V2G score. B) Selected phenotypes associated with genome-wide significant COVID-
19 variants (see Supplementary Table 5 for a complete list). We report those associations for which a lead 
variant from a prior GWAS results was in high LD  (r2 > 0.8) with the index COVID-19 variants. The colour 
represents the Z-scores of correlated risk increasing alleles  for the trait. The total number of associations 
for each COVID-19 variant is highlighted in the grey box.  
 
 
Polygenic architecture of COVID-19 
 
To further investigate the genetic architecture of COVID-19, we used results from meta-analyses including 
only European ancestry samples (sample sizes described in Methods and Supplementary Table 1). We 
applied linkage disequilibrium (LD) score regression 35 to the summary statistics to estimate SNP 
heritability, i.e.  proportion of variation in the two phenotypes that was attributable to common genetic 
variants, and to determine whether heritability for COVID-19 phenotypes was enriched in genes 
specifically expressed in certain tissues 36 from GTEx dataset 37. We detected a low, but significant 
heritability across all three analyses (<1% on observed scale, all P-values < 0.0001; Supplementary Table 
6). Despite these low values, which interpretation is complicated by the use of population controls and 
variation in the disease prevalence estimates, we found that heritability for reported infection was 
significantly enriched in genes specifically expressed in the lung (P = 5.0 × 10-4) (Supplementary Table 
7). These findings, together with genome-wide significant loci identified in the meta-analyses, illustrate 
that there is a significant polygenic or oligogenic architecture that can be better leveraged with future, 
larger, sample sizes.      
 
 
Genetic correlation and causal relationship between COVID-19 and other traits 
 
Genetic correlations (rg) between the three COVID-19 phenotypes was high, though lower correlations 
were observed between hospitalized COVID-19 and reported infection (critical illness vs. hospitalized: rg  
[95%CI] = 1.37 [1.08, 1.65], P = 2.9 × 10-21; critical illness vs. reported infection, rg  [95%CI] = 0.96 [0.71, 
1.20], P = 1.1 × 10-14; hospitalized vs. reported infection: rg [95%CI] = 0.85 [0.68, 1.02], P = 1.1 × 10-22). 
To better understand which traits are genetically correlated and/or potentially causally associated with 
COVID-19 severity and SARS-CoV-2 reported infection, we chose a set of 38 disease, health and 
neuropsychiatric phenotypes as potential COVID-19 risk factors based on their putative relevance to the 
disease susceptibility, severity, or mortality (Supplementary Table 8).  
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We found evidence (FDR<0.05) of significant genetic correlations between 9 traits and hospitalized 
COVID-19 and SARS-CoV-2 reported infection (Fig. 4;  Supplementary Table 9). Genetic correlation 
results for COVID-19 severity partially overlap with reported SARS-CoV-2 infection, with genetic liability 
to BMI, type 2 diabetes, smoking, and attention deficit hyperactivity disorder showing significant positive 
correlations (rg range between 0.16 - 0.26). However some results were significantly different between 
COVID-19 severity and reported infection. For example, genetic liability to ischemic stroke, was only 
significantly positively correlated with critical illness or hospitalization due to to COVID-19, but not with 
a higher likelihood of reported SARS-CoV-2 infection (infection r g= 0.019 vs. hospitalization rg = 0.41, z 
= 2.7, P = 0.006; infection rg = 0.019 vs. critical illness rg = 0.40, z = 2.49, P = 0.013). In addition, coronary 
artery disease, and systemic lupus erythematosus showed positive genetic correlations with critical illness 
or hospitalization due to COVID-19. Genetic liability to risk tolerance, on the hand, was the only trait 
specifically associated with SARS-CoV-2 infection. This potentially reflects that risk taking behavior could 
be associated with a higher chance of infection, but is not, per-se, impacting the chances to develop a severe 
form of COVID-19. With improved phenotyping of cases and controls, methods to deconvolute the effects 
specific to SARS-CoV-2 infection - a proxy for disease susceptibility - and those specific for progression 
to severe disease can be applied to better interpret these results. 
 
We next used two-sample Mendelian randomization (MR) to infer potentially causal relationships between 
these traits. Fixed-effects IVW analysis was used as the primary analysis 38, with weighted median estimator 
(WME) 39, weighted mode based estimator (WMBE) 40, MR Egger regression 41 and MR-PRESSO 42 outlier 
corrected estimates used as additional sensitivity analyses.  
 
After correcting for multiple testing (FDR < 0.05), 8 exposure — COVID-19 trait-pairs showed suggestive 
evidence of a causal association (Fig. 4; Supplementary Table 10a). Five of these associations were robust 
to potential violations of the underlying assumptions of MR.  Corroborating our genetic correlation results 
and evidence from traditional epidemiological studies, genetically predicted higher BMI (OR [95%CI] 1.4 
[1.3, 1.6], P = 8.5 × 10-11) and smoking (OR [95%CI] = 1.9 [1.3, 2.8], P = 0.0012) were associated with 
increased risk of COVID-19 hospitalization, with BMI also being associated with increased risk of SARS-
CoV-2 infection (OR [95%CI] = 1.1 [1.1, 1.2], P = 4.8 × 10-7). Genetically predicted increased height (OR 
[95%CI] = 1.1 [1, 1.1]), P = 8.9 × 10-4) was associated with an increased risk of reported infection, and 
genetically predicted higher red blood cell count (OR [95%CI] = 0.93 [0.89, 0.96], P = 5.7 × 10-5) was 
associated with a reduced risk of reported infection.  
 
We noted that there was sample overlap between some datasets used to generate exposures used in the 
previous analysis, and the samples contributing to our meta-analysis of hospitalized COVID-19, as a result 
of inclusion of samples from the UK Biobank. We therefore conducted an additional sensitivity analysis, 
using new hospitalized COVID-19 summary statistics in which the UK Biobank study had been removed 
(Supplementary Table 10b). In this analysis, genetically predicted BMI, height, and red blood cell counts 
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Figure 4. Genetic correlations and Mendelian randomization causal estimates between 43 traits and 
COVID-19 severity and SARS-CoV-2 reported infection. Blue, negative genetic correlation and protective 
Mendelian randomization (MR) causal estimates; red, positive genetic correlation and risk MR causal 
estimates. Larger squares correspond to more significant P values, with genetic correlations or MR causal 
estimates significantly different from zero at a P < 0.05 shown as a full-sized square. Genetic correlations 
or causal estimates that are significantly different from zero at a false discovery rate (FDR) of 5% are 
marked with an asterisk. Forest plots display the causal estimates for each of the sensitivity analyses used 
in the MR analysis for trait pairs that were significant at an FDR of 5%. Individual scatter and funnel plots 
for each pair of traits are available in Extended Data Fig. 4. 
IVW: Inverse variance weighted analysis; WME: Weighted median estimator; WMBE: weighted mode 
based estimator; MR-PRESSO: Mendelian Randomization Pleiotropy RESidual Sum and Outlier. RBC: 
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The COVID-19 Host Genetics Initiative has brought together investigators from across the world to to 
advance genetic discovery for SARS Cov2 infection and severe COVID-19 disease.We report 15 genome-
wide significant loci associated with some aspect of SARS Cov2 infection or COVID-19. Many of these 
loci overlap with previously reported associations with lung-related phenotypes or 
autoimmune/inflammatory diseases, but some loci have no obvious candidate gene as yet.  
 
Four out of the 15 genome-wide significant loci showed similar effects in the reported infection analysis (a 
proxy for disease susceptibility) and all-hospitalized COVID-19 (a proxy for disease severity). This 
supports the notion that some genetic variants, most notably at ABO and PPP1R15A loci, might indeed 
impact susceptibility to infection rather than progression to a severe form of the disease once infected. 
Whilst our ability to draw definitive conclusions is impaired by incomplete capture of who has been infected 
with SARS-CoV-2, a recent study based on self-reported exposure to COVID-19 positive housemate and 
consequent development of the disease, support our findings 43.   
 
Several of the loci reported here, as noted in previous publications, intersect with well-known genetic 
variants that have established genetic associations. Variants at DPP9 show prior evidence of increasing risk 
for interstitial lung disease.  Missense variants within TYK2 show a protective effect on several 
autoimmune-related diseases. Variants overlapping the well-known structural variants-rich 17q21.31 locus 
have been previously associated with pulmonary function. Together with the heritability enrichment 
observed in genes expressed in lung tissues, these results highlight the involvement of lung-related 
biological pathways in developing severe COVID-19. Several other loci show no prior documented 
genome-wide significant associations, even despite the high significance and attractive candidate genes for 
COVID-19 (e.g., CXCR6, LZTFL1, IFNAR2 and OAS1/2/3 loci). The previously reported associations for 
the strongest signal for COVID-19 severity at 3p21.31 and monocytes count are likely to be due to 
proximity and not a true co-localization. 
 
Increasing the global representation in genetic studies enhances the ability to detect novel associations. Two 
of the loci affecting disease severity were only discovered by including the four studies of individuals with 
East Asian ancestry. One of these loci, close to FOXP4, is common particularly in East Asian (40%) as 
well as Middle Eastern and Admixed American samples in the Americas but has a low frequency in most 
European populations (2-3%). Previous studies have reported association between this locus and lung 
cancer 29,44 and interstitial lung disease 45. Although we cannot be certain of the mechanism of action of this 
association FOXP4 is an attractive biological target, as it is expressed in the proximal and distal airway 
epithelium 46, and has been shown to play a role in controlling epithelial cell fate during lung development 
47.  
 
A central challenge for the COVID-19 HGI was the harmonization of phenotype definitions, analytic 
pipelines and cohorts with extremely heterogeneous designs, sample ascertainment and control populations. 
Large-scale biobanks with existing genotype resources and connections to medical systems, newly enrolled 
hospital-based studies (particularly well-powered to study the extremes of severity by through the 
recruitment of individuals from intensive care units), and direct-to-consumer genetics studies with customer 
surveys each contributed different aspects to understanding the genetic basis of susceptibility and severity 
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traits. Indeed, working together through aligning phenotype definitions and sharing results accelerated 
progress and has enhanced the robustness of the reported findings.  
 
Nevertheless, the differences in study sample size, ascertainment and phenotyping of COVID-19 cases are 
unavoidable and care should be taken when interpreting the results from a meta-analysis. First, studies 
enriched with severe cases or studies with antibody-tested controls may disproportionately contribute to 
genetic discovery despite potentially smaller sample sizes. Second, differences in genomic profiling 
technology, imputation, and sample size across the constituent studies can have dramatic impacts on 
replication and downstream analyses (particularly fine-mapping where differential missing patterns in the 
reported results can muddy the signal). Third, the use of population controls with no complete information 
about SARS-CoV-2 exposure might result in cases of misclassification or reflect ascertainment biases in 
testing and reporting rather than true susceptibility to infection. Genotyping large numbers of control 
samples who have been exposed to the virus but remained asymptomatic or experienced only mild 
symptoms is challenging. Therefore, many studies prefer to use pre-existing datasets of genetically 
ancestry-matched samples as their controls, protecting against population stratification, but potentially 
introducing some of these biases. Our analysis comparing the discovery meta-analysis effects to one where 
controls were phenotypically refined, indicated that, for genome-wide significant variants, such bias was 
limited.     
 
Drawing a comprehensive and reproducible map of the host genetics factors associated with COVID-19 
severity and SARS-CoV-2 requires a sustained international effort to include diverse ancestries and study 
designs. The number of COVID-19 study participants and studies contributing data to this study illustrate 
the benefits of worldwide international collaboration, open governance and planning, and sharing of 
technological and analytical resources. To expedite downstream scientific research and therapeutic 
discovery, the COVID-19 Host Genetic Initiative regularly publishes meta-analysis results from periodic 
data freezes on the website www.covid19hg.org as new data are included in the study. We also provide an 
interactive explorer where researchers can browse the results and the genomic loci in more detail. Future 
work will be required to better understand the biological and clinical value of these findings. Continued 
efforts to collect more samples and detailed phenotypic data should be endorsed globally; allowing for more 
thorough investigation of variable, heritable symptoms 48,49, particularly in the light of newly emerging 
strains of SARS-CoV-2 virus, which may provoke different host responses leading to disease, and with the 
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In total 16 studies contributed data to analysis of critical illness due to COVID-19, 29 studies contributed 
data to hospitalized COVID-19 analysis, and 44 studies contributed to the analysis of all COVID-19 cases. 
Details of contributing research groups are described in Supplementary Table 1. All subjects were 
recruited following protocols approved by local Institutional Review Boards (IRBs). All protocols followed 





COVID-19 disease status (critical illness, hospitalization status) was assessed following the Diagnosis and 
Treatment Protocol for Novel Coronavirus Pneumonia 50. The critically ill COVID-19 group included 
patients who were hospitalized due to symptoms associated with laboratory-confirmed SARS-CoV-2 
infection and who required respiratory support or whose cause of death was associated with COVID-19. 
The hospitalized COVID-19 group included patients who were hospitalized due to symptoms associated 
with laboratory-confirmed SARS-CoV-2 infection.  
The reported infection cases group included individuals with laboratory-confirmed SARS-CoV-2 infection 
or electronic health record, ICD coding or clinically confirmed COVID-19, or self-reported COVID-19 
(e.g. by questionnaire), with or without symptoms of any severity.  Genetic ancestry-matched controls for 
the three case definitions were sourced from population-based cohorts, including individuals whose 
exposure status to SARS-CoV-2 was either unknown or infection- negative for questionnaire/electronic 
health record-based cohorts. Additional information regarding individual studies contributing to the 
consortium are described in Supplementary Table 1.  
 
 
GWAS and meta-analysis 
 
Each contributing study genotyped the samples and performed quality controls, data imputation and 
analysis independently, but following consortium recommendations (information available at 
www.covid19hg.org). We recommended to run GWAS analysis using Scalable and Accurate 
Implementation of GEneralized mixed model (SAIGE) 51 on chromosomes 1-22 and X. The recommended 
analysis tool was SAIGE, but studies also used other software such as PLINK 52. The suggested covariates 
were age, age2, sex, age*sex, and 20 first principal components. Any other study-specific covariates to 
account for known technical artefacts could be added. SAIGE automatically accounts for sample 
relatedness and case-control imbalances. Individual study quality control and analysis approaches are 
reported in Supplementary Table 1. 
 
Study-specific summary statistics were then processed for meta-analysis. Potential false positives, inflation, 
and deflation were examined for each submitted GWAS. Standard error values as a function of effective 
sample size was used to find studies which deviated from the expected trend. Summary statistics passing 
this manual quality control were included in the meta-analysis. Variants with allele frequency of >0.1% and 
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imputation INFO>0.6 were carried forward from each study. Variants and alleles were lifted over to genome 
build GRCh38, if needed, and harmonized to gnomAD 3.0 genomes 53 by finding matching variants by 
strand flipping or switching ordering of alleles. If multiple matching variants, the best match was chosen 
by minimum absolute allele frequency fold change. Meta-analysis was performed using the inverse-
variance weighted method. The method summarizes effect sizes across the multiple studies by computing 
the mean of the effect sizes weighted by the inverse variance in each individual study.  
 
For each of the 15 independent lead variants reported in Table 1, we tested whether there was heterogeneity 
between the effect sizes associated with hospitalized COVID-19 (progression to severe disease) and 
reported SARS-CoV-2 infection. We used Cochran's Q measure 54,55, which is calculated for each variant 
as the weighted sum of squared differences between the two analysis effects sizes and their meta-analysis 
effect, the weights being the inverse variance of the effect size. Q is distributed as a chi-square statistic with 
k (number of studies) minus 1 degrees of freedom. A significant P-value <0.003 (0.05/15 for multiple tests) 
indicates that the effect sizes for a particular variant are significantly different in the two analyses. For the 
11 loci, where the lead variant effect size was significantly higher for hospitalized COVID-19, we carried 
out the same test again but comparing effect sizes from hospitalized COVID-19 with critically ill COVID-
19 (Supplementary Table 3). Further, we carried out the same test comparing meta-analyzed hospitalized 
COVID-19 (population as controls) and hospitalized COVID-19 (SARS-Cov-2 positive but non-
hospitalized as controls) (Supplementary Table 3). For these pairs of phenotype comparisons, we 
generated new meta-analysis summary statistics to use; including only those studies that could contribute 





To prioritize candidate causal genes, we employed various gene prioritization approaches using both locus-
based and similarity-based methods. Because we only referred in-silico gene prioritization results without 
characterizing actual functional activity in-vitro/vivo, we aimed to provide a conservative list of any 
potential causal genes in a locus using the following criteria: 
1. Closest gene: a gene that is closest to a lead variant by distance to the gene body 
2. Genes in LD region: genes that overlap with a genomic range containing any variants in LD (r2 > 
0.6) with a lead variant. For LD computation, we retrieved LD matrices provided by the gnomAD 
v2.1.1 53 for each population analyzed in this study (except for Admixed American, Middle Eastern, 
and South Asian that are not available). We then constructed a weighted-average LD matrix by per-
population sample sizes in each meta-analysis, which we used as a LD reference. 
3. Genes with coding variants: genes with at least one loss of function or missense variant (annotated 
by VEP 56 v95 with GENCODE v29) that is in LD with a lead variant (r2 > 0.6). 
4. eGenes: genes with at least one fine-mapped cis-eQTL variant (PIP > 0.1) that is in LD with a lead 
variant (r2 > 0.6) (Supplementary Table 4). We retrieved fine-mapped variants from the GTEx 
v826 (https://www.finucanelab.org/) and eQTL catalogue57. In addition, we looked up significant 
associations in the Lung eQTL Consortium 27 (n = 1,103) to further support findings in lung with a 
larger sample size (Supplementary Table 11). We note that, unlike the GTEx or eQTL catalogue, 
we only looked at associations and didn’t finemap in the Lung eQTL Consortium data. 
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5. V2G: a gene with the highest overall Variant-to-Gene (V2G) score based on the Open Targets 
Genetics (OTG) 23.  For each variant, the overall V2G score aggregates differentially weighted 
evidence of variant-gene association from several data sources, including molecular cis-QTL data 
(e.g., cis-pQTLs from 58., cis-eQTLs from GTEx v7 etc.), interaction-based datasets (e.g., Promoter 
Capture Hi-C), genomic distance, and variant effect predictions (VEP) from Ensembl. A detailed 




Phenome-wide association study  
 
To investigate the evidence of shared effects of 15 index variants for  COVID-19 and previously reported 
phenotypes, we performed a phenome-wide association study. We considered phenotypes in (Open Target) 
OTG obtained from the GWAS catalog (this included studies with and without full summary statistics, n = 
300 and 14,013, respectively) 60, and from UK Biobank. Summary statistics for UK Biobank traits were 
extracted from SAIGE 51 for binary outcomes (n = 1,283 traits), and Neale v2 (n = 2,139 traits) for both 
binary and quantitative traits (http://www.nealelab.is/uk-biobank/)and FinnGen Freeze 4 cohort 
(https://www.finngen.fi/en/access_results). To remove plausible spurious associations, we retrieved 





LD score regression v 1.0.1 35 was used to estimate SNP heritability of the phenotypes from the meta-
analysis summary statistic files. As this method depends on matching the linkage disequilibrium (LD) 
structure of the analysis sample to a reference panel, the European-only summary statistics were used. 
Sample sizes were n = 5,101 critically ill COVID-19 cases and n = 1,383,241 controls,  n = 9,986 
hospitalized COVID-19 cases and n = 1,877,672 controls, and n = 38,984 cases and n = 1,644,784 controls 
for all cases analysis, all including the 23andMe cohort. Pre-calculated LD scores from the 1000 Genomes 
European reference population were obtained online 
(https://data.broadinstitute.org/alkesgroup/LDSCORE/). Analyses were conducted using the standard 
program settings for variant filtering (removal of non-HapMap3 SNPs, non-autosomal, chi-square > 30, 
MAF < 1%, or allele mismatch with reference). We additionally report SNP heritability estimates for the 
all-ancestries meta-analyses, calculated using European panel LD scores,  in Supplementary Table 6.  
 
 
Partitioned heritability  
 
We used partitioned LD score regression 61 to partition COVID-19 SNP heritability in  cell types in our 
European-only summary statistics. We ran the analysis using the baseline model LD scores calculated for 
European populations and regression weights that are available online. We used the COVID-19 European 
only summary statistics for the analysis. 
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Genome-wide association summary statistics  
 
We obtained genome-wide association summary statistics for 43 complex disease, neuropsychiatric, 
behavioural, or biomarker phenotypes (Supplementary Table 8). These phenotypes were selected based 
on their putative relevance to COVID-19 susceptibility, severity, or mortality, with 19 selected based on 
the Centers for Disease Control list of underlying medical conditions associated with COVID-19 severity 
62 or traits reported to be associated with increased risk of COVID-19 mortality by OpenSafely 63. Summary 
statistics generated from GWAS using individuals of European ancestry were preferentially selected if 
available. These summary statistics were used in subsequent genetic correlation and Mendelian 





LD score regression 61 was also used to estimate genetic correlations between our COVID-19 meta-analysis 
phenotypes reported using European-only samples, and between these and the curated set of 38 summary 
statistics. Genetic correlations were estimated using the same LD score regression settings as for heritability 
calculations. Differences between the observed genetic correlations of SARS-COV2 infection and COVID-
19 severity were compared using a z score method 64.   
 
 
Mendelian Randomization  
 
Two-sample Mendelian randomization was employed to evaluate the causal association of the 38 traits on 
COVID-19 hospitalization, on COVID-19 severity and SARS-CoV-2 reported infection using European-
only samples. Independent genome-wide significant SNPs robustly associated with the exposures of interest 
(P < 5 × 10-8) were selected as genetic instruments by performing LD clumping using PLINK 52. We used 
a strict r2 threshold of 0.001, a 10MB clumping window, and the European reference panel from the 1000 
Genomes project 65 to discard SNPs in linkage disequilibrium with another variant with smaller p-value 
association. For genetic variants that were not present in the hospitalized COVID analysis, PLINK was 
used to identify proxy variants that were in LD (r2 > 0.8). Next, the exposure and outcome datasets were 
harmonized using the R-package TwoSampleMR 66. Namely, we ensured that the effect of a variant on the 
exposure and outcome corresponded to the same allele, we inferred positive strand alleles and dropped 
palindromes with ambiguous allele frequencies, as well as incompatible alleles. Supplementary Table 8 
includes the harmonized datasets used in the analyses.      
 
Mendelian Randomization Pleiotropy residual sum and outlier (MR-PRESSO) Global test 42 was used to 
investigate overall horizontal pleiotropy. In short, the standard IVW meta-analytic framework was 
employed to calculate the average causal effect by excluding each genetic variant used to instrument the 
analysis. A global statistic was calculated by summing the observed residual sum of squares, i.e., the 
difference between the effect predicted by the IVW slope excluding the SNP, and the observed SNP-effect 
on the outcome. Overall horizontally pleiotropy was subsequently probed by comparing the observed 
residual sum of squares, with the residual sum of squares expected under the null hypothesis of no 
pleiotropy. The MR-PRESSO Global test was shown to perform well when the outcome and exposure 
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GWASs are not disjoint (although the power to detect horizontal pleiotropy is slightly reduced by complete 
sample overlap). We also used the MR-Egger regression intercept 41 to evaluate potential bias due to 
directional pleiotropic effects. This additional check was employed in MR analyses with an 𝐼𝐺𝑋
2 index 
surpassing the recommended threshold (𝐼𝐺𝑋
2  > 90%; 67). Contingent on the MR-PRESSO Global test results 
we probed the causal effect of each exposure on COVID-19 hospitalization by using a fixed effect inverse-
weighted (IVW) meta-analysis as the primary analysis, or, if pleiotropy was present, the MR-PRESSO 
outlier corrected test. The IVW approach estimates the causal effect by aggregating the single-SNP causal 
effects (obtained using the ratio of coefficients method, i.e., the ratio of the effect of the SNP on the outcome 
on the effect of the SNP on the exposure) in a fixed effects meta-analysis. The SNPs were assigned weights 
based on their inverse variance. The IVW method confers the greatest statistical power for estimating causal 
associations 68, but assumes that all variants are valid instruments and can produce biased estimates if the 
average pleiotropic effect differs from zero. Alternatively, when horizontal pleiotropy was present, we used 
MR-PRESSO Outlier corrected method to correct the IVW test by removing outlier SNPs. We conducted 
further sensitivity analyses using alternative MR methods that provide consistent estimates of the causal 
effect even when some instrumental variables are invalid, at the cost of reduced statistical power including: 
1) Weighted Median Estimator (WME); 2) Weighted Mode Based Estimator (WMBE); 3) MR-Egger 
regression. Robust causal estimates were defined as those that were significant at an FDR of 5% and either 
1) showed no evidence of heterogeneity (MR-PRESSO Global test P > 0.05) or horizontal pleiotropy (Egger 
Intercept P > 0.05), or 2) in the presence of heterogeneity or horizontal pleiotropy, either the WME, WMBE, 
MR-Egger or MR-PRESSO corrected estimates were significant (P < 0.05). All statistical analyses were 
conducted using R version 4.0.3. MR analysis was performed using the “TwoSampleMR” version 0.5.5 
package 66.  
 
 
Website and data distribution 
 
In anticipation of the need to coordinate many international partners around a single meta-analysis effort, 
we created the COVID-19 HGI website (https://covid19hg.org). We were able to centralize information, 
recruit partner studies, rapidly distribute summary statistics, and present preliminary interpretations of the 
results to the public. Open meetings are held on a monthly basis to discuss future plans and new results; 
video recordings and supporting documents are shared (https://covid19hg.org/meeting-archive). This 
centralized resource provides a conceptual and technological framework for organizing global academic 
and industry groups around a shared goal. The website source code and additional technical details are  
available at https://github.com/covid19-hg/covid19hg. 
 
To recruit new international partner studies, we developed a workflow whereby new studies are registered 
and verified by a curation team (https://covid19hg.org/register). Users can explore the registered studies 
using a customized interface to find and contact studies with similar goals or approaches 
(https://covid19hg.org/partners). This helps to promote organic assembly around focused projects that are 
adjacent to the centralized effort (https://covid19hg.org/projects). Visitors can query study information, 
including study design and research questions. Registered studies are visualized on a world map and are 
searchable by institutional affiliation, city, and country.  
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To encourage data sharing and other forms of participation, we created a rolling acknowledgements page 
(https://covid19hg.org/acknowledgements) and directions on how to contribute data to the central meta-
analysis effort (https://covid19hg.org/data-sharing). Upon the completion of each data freeze, we post 
summary statistics, plots, and sample size breakdowns for each phenotype and contributing cohort 
(https://covid19hg.org/results). The results can be explored using an interactive web browser 
(https://app.covid19hg.org). Several computational research groups carry out follow-up analyses, which are 
made available for download (https://covid19hg.org/in-silico). To enhance scientific communication to the 
public, preliminary results are described in blog posts by the scientific communications team and shared on 
Twitter. The first post was translated to 30 languages with the help of 85 volunteering translators. We 
compile publications and preprints submitted by participating groups and summarize genome-wide 




We thank the entire COVID-19 Host Genetics Initiative community for their contributions and continued 
collaboration. The work of the contributing studies was supported by numerous grants from governmental 
and charitable bodies, and study specific acknowledgements will be released with the publication. We thank 
G. Butler-Laporte, G. Wojcik, M.-G. Hollm-Delgado, C. Willer and G. Davey Smith for their extensive 




Summary statistics generated by COVID-19 HGI are available at https://www.covid19hg.org/results/r5/ 
and will be made available on GWAS Catalog. The analyses described here utilize the freeze 5 data. 
COVID-19 HGI continues to regularly release new data freezes. Summary statistics for non-European 
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Extended Data Figure 1. Sensitivity analyses for overlapping controls in genomiCC and UK 
Biobank. 
Comparison of the effect sizes and P-values of the 15 lead variant, using data from the COVID-19 critical 
illness meta-analysis in all the cohorts (y-axis) to leaving out genomiCC, leaving out UK Biobank 
(UKBB) and leaving out genomiCC + UKBB, respectively (x-axis). Dots represent the effect size 
estimates (top panels) and P-values (bottom panels), and bars represent the standard error. Filled dots 
indicate variants that were significant in the full meta-analysis of critical illness due to COVID-19, and 
empty dots represent variants that were not significant for critical illness but were significant for either 
hospitalization due to COVID-19  or SARS-CoV-2 reported infection. Red dots represent variants that 
were significant in leave-one-out analysis for genomiCC, UKBB or genomiCC + UKBB.  
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Extended Data Figure 2. Comparison of lead variant effect sizes between pairs of COVID-19 meta-
analyses. 
Comparison of effect sizes for the 11 variants associated with severity of COVID-19 disease. A. 
Comparing hospitalized COVID-19 cases vs population controls (x-axis, n=10,428 cases and n=1,483,270 
controls) and critically ill COVID-19 cases vs population controls (y-axis, n=6,179 cases and 
n=1,483,780 controls). B. hospitalized COVID-19 cases vs population controls (x-axis,n=5,806 cases and
 n=1,144,263 controls)and hospitalized COVID-19 cases vs non-hospitalized COVID-19 cases (y-
axis, n=5,773 and n=15,497 controls). Dots represent the effect size estimates, bars represent the 
confidence interval of the estimates. Effect size estimates and P-values for heterogeneity test are reported 
in Supplementary Table 3.   
 
 
Please find the corresponding figure in the supplementary PDF “Extended Data Figure 3”  
Extended Data Figure 3. LocusZoom plots for each COVID-19 locus in three meta-analyses. 
For each genome-wide significant locus in three meta-analyses: critical illness (labelled as Analysis A2), 
hospitalization (labelled as Analysis B2), and reported infection (labelled as Analysis C2), we showed 1) 
a manhattan plot of each locus where a color represents a weighted-average r2 value (see Methods) to a 
lead variant; 2) r2 values to a lead variant across gnomAD v2 populations, i.e., African/African-American 
(AFR), Latino/Admixed American (AMR), Ashkenazi Jewish (ASJ), East Asian (EAS), Estonian (EST), 
Finnish (FIN), Non-Finish Europeans (NFE), North-Western Europeans (NWE), and Southern Europeans 
(SEU); 3) genes at a locus; and 4) genes prioritized by each gene prioritization metric where a size of 
circles represents a rank in each metric. Note that the COVID-19 lead variants were chosen across all the 
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meta-analyses (Table 1; see Methods) and were not necessarily a variant with the most significant P-
value in each meta-analysis. 
 
Please find the corresponding figure in the supplementary PDF “Extended Data Figure 4”  
Extended Data Figure 4. Scatter and funnel plots for each for exposure - COVID-19 outcome pair. 
Scatter plots show the exposure variant effect size against the COVID-19 outcome variant effect size and 
corresponding standard errors. Funnel plots show the Mendelian randomization (MR) causal estimates for 
each variant against their precision, with asymmetry in the plot indicating potential violations of the 
assumptions of MR. Regression lines show the corresponding causal estimates fixed effect inverse-
weighted (IVW, red-solid line) meta-analysis; MR-Egger regression (blue-dashed); Weighted median 
estimator (WME, green-dashed); weighted mode based estimator (WMBE, purple dashed); and 
Mendelian Randomization Pleiotropy RESidual Sum and Outlier corrected (MR-PRESSO, orange 
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